A1-2: Cost-Effectiveness of Interleukin 28B Genotype-Guided Protease Inhibitor Therapy in Treatment-Naïve Patients with Hepatitis C Virus Genotype 2 or 3

  • Clinical Medicine & Research
  • September 2013,
  • 11
  • (3)
  • 142;
  • DOI: https://doi.org/10.3121/cmr.2013.1176.a1-2
Back to top

In this Issue

Clinical Medicine & Research

Clinical Medicine & Research

Vol. 11, Issue 3

1 Sep 2013

Table of Contents Cover (Photo) Index by author

Jump to

Keywords

Economics, Cost Modeling, Pharmacogenomics